BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage ...
BioLineRx Ltd., a clinical-stage biopharmaceutical company specializing in oncology and rare diseases, is advancing GLIX1 as its lead asset, targeting DNA damage response in glioblastoma and other ...
Stocktwits on MSN
BLRX stock surges pre-market on cancer trial catalyst – eyes 50-DMA breakout for first time in nearly 2 months
BioLineRx partnered with Hemispherian to conduct a trial testing GLIX1 in patients with Glioblastoma. ・Early preclinical data showed strong anti-tumor activity, good brain penetration, and a favorable ...
(RTTNews) - BioLineRx Ltd. (BLRX) said that phase 1/2a Study of investigational anti-tumor vaccine AGI-134 in unresectable metastatic solid tumors met its primary endpoint of safety and tolerability.
BioLineRx is utilizing its end-to-end expertise in development, regulatory affairs, manufacturing and commercialization to advance its innovative pipeline and ensure life-changing discoveries move ...
TEL AVIV, Israel, March 16, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and ...
TEL AVIV, Israel, May 30, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare disease, today ...
Bioline RX Ltd Sponsored ADR ( (BLRX)) has released its Q3 earnings. Here is a breakdown of the information Bioline RX Ltd Sponsored ADR presented to its investors. Unlock your investing potential ...
View BioLineRX Ltd. Sponsored ADR BLRX stock quote prices, financial information, real-time forecasts, and company news from CNN.
BioLineRx Ltd. (NASDAQ:BLRX) Q2 2025 Earnings Call Transcript August 14, 2025 BioLineRx Ltd. misses on earnings expectations. Reported EPS is $-1 EPS, expectations were $-0.35. Operator: Ladies and ...
Patient was dosed at NYU Langone Health under the supervision of Dr. Alexandra Miller, Chief of Neuro-Oncology & Co-Director of Brain and Spine Tumor Center, Perlmutter Cancer CenterData ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results